Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study

Xinran Ma,* Ling Li,* Lei Zhang, Xiaorui Fu, Xin Li, Xinhua Wang, Jingjing Wu, Zhenchang Sun, Xudong Zhang, Xiaoyan Feng, Yu Chang, Zhiyuan Zhou, Feifei Nan, Jieming Zhang, Zhaoming Li, Mingzhi Zhang Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Lymphoma Diagnosis an...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ma X, Li L, Zhang L, Fu X, Li X, Wang X, Wu J, Sun Z, Zhang X, Feng X, Chang Y, Zhou Z, Nan F, Zhang J, Li Z, Zhang M
Format: Artigo
Jezik:Inglês
Izdano: Dove Medical Press 2020-01-01
Serija:Drug Design, Development and Therapy
Teme:
apatinib
relapsed or refractory diffuse large b-cell lymphoma
vegfr-2
efficacy
safety
Online pristup:https://www.dovepress.com/apatinib-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell--peer-reviewed-article-DDDT
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items